COMPANY 33
| Company Name | ||||||
|---|---|---|---|---|---|---|
| Eli Lilly | 89,752 | $646,718,443 | -8% | $193,794,660 | 54 | |
| Merck | 99,802 | $501,062,741 | -3% | $218,342,319 | 54 | |
| Pfizer | 219,612 | $275,822,858 | 15% | $50,709,308 | 53 | |
| Glaxosmithkline | 60,982 | $163,922,924 | 9% | $14,624,413 | 54 | |
| Allergan | 51,805 | $124,977,905 | 2% | $46,628,136 | 52 | |
| AstraZeneca | 127,918 | $113,045,075 | 37% | $41,659,493 | 54 | |
| Janssen Pharmaceuticals | 145,078 | $83,079,578 | 123% | $45,396,457 | 52 | |
| Novartis | 28,653 | $82,851,203 | $82,851,203 | 53 | ||
| AbbVie | 67,543 | $60,952,916 | 140% | $42,983,598 | 53 | |
| UCB | 18,723 | $58,257,524 | -18% | $26,205,834 | 52 | |
| Forest Laboratories | 71,447 | $37,253,795 | $37,253,795 | 52 | ||
| Boston | 9,856 | $35,319,797 | $35,319,797 | 52 | ||
| Boehringer Ingelheim | 57,136 | $22,726,797 | $22,726,797 | 52 | ||
| Depuy Mitek | 246 | $22,252,453 | 44 | |||
| Janssen Biotech | 1,123 | $20,887,806 | -9% | $5,102,912 | 49 | |
| Ethicon Endo-Surgery | 534 | $16,572,380 | 42 | |||
| Amgen | 47,595 | $14,954,995 | $14,954,995 | 52 | ||
| Valeant | 14,696 | $12,544,397 | 58% | $6,679,723 | 52 | |
| ViiV Healthcare | 411 | $10,861,258 | -37% | $1,306,638 | 39 | |
| Cordis | 152 | $9,113,341 | 36 |
www.gbihealth.com
Suite 301, Building 2, 169 Mengzi Rd.
Shanghai 200023, P.R. China
(8621) 5302 2951
(8621) 5302 2950
CONTACT GBI
© 2014 GB Group Limited. All Rights Reserved.
Terms of Service
Privacy Policy